In what tumor subtypes -- based on what molecular targets (BRAF, EGFR, MEK, ALK-1, etc) has hybrid capture-based NGS been validated as a foundational diagnostic test that leads to better response rates and improved overall survival?

In what tumor subtypes -- based on what molecular targets (BRAF, EGFR, MEK, ALK-1, etc) has hybrid capture-based NGS been validated as a foundational diagnostic test that leads to better response rates and improved overall survival?

In what tumor subtypes — and based on what specific molecular targets (BRAF, EGFR, MEK, ALK-1 and others, including MSI) has hybrid capture-based NGS been validated as a foundational diagnostic test that leads to better response rates, PFS, and improved overall survival?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Razelle Kurzrock, MD

Razelle Kurzrock, MD

Chief, Division of Hematology and Oncology
UCSD School of Medicine
Senior Deputy Director, Clinical Science
Director, Center for Personalized Cancer Therapy
Director, Clinical Trials Office
UCSD Moores Cancer Center
San Diego, California